[HTML][HTML] An overview of mobile applications (apps) to support the coronavirus disease 2019 response in India
Methods: Google Play and the Apple app stores were searched using the terms' COVID-19','coronavirus','pandemic',
and'epidemic'in the first week of April 2020. A list of COVID-19-…
and'epidemic'in the first week of April 2020. A list of COVID-19-…
[HTML][HTML] Current status and future directions of mHealth interventions for health system strengthening in India: systematic review
Background: With the exponential increase in mobile phone users in India, a large number
of public health initiatives are leveraging information technology and mobile devices for …
of public health initiatives are leveraging information technology and mobile devices for …
Higher vs lower doses of dexamethasone in patients with COVID‐19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan
…, S Micallef, A Bassi, O John… - Acta …, 2021 - Wiley Online Library
Background The coronavirus disease 2019 (COVID‐19) pandemic has resulted in millions
of deaths and overburdened healthcare systems worldwide. Systemic low‐dose …
of deaths and overburdened healthcare systems worldwide. Systemic low‐dose …
[HTML][HTML] Role of artificial intelligence within the telehealth domain
C Kuziemsky, AJ Maeder, O John… - Yearbook of medical …, 2019 - thieme-connect.com
Objectives: This paper provides a discussion about the potential scope of applicability of
Artificial Intelligence methods within the telehealth domain. These methods are focussed on …
Artificial Intelligence methods within the telehealth domain. These methods are focussed on …
The 2020 “WHO technical specifications for automated non-invasive blood pressure measuring devices with cuff”
O John, NRC Campbell, TM Brady, M Farrell… - …, 2021 - Am Heart Assoc
High systolic blood pressure (BP) is the single leading modifiable risk factor for death
worldwide. Accurate BP measurement is the cornerstone for screening, diagnosis, and …
worldwide. Accurate BP measurement is the cornerstone for screening, diagnosis, and …
[HTML][HTML] Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID …
…, NE Hammond, S Micallef, A Bassi, O John… - Intensive care …, 2022 - Springer
Purpose We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients
with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, …
with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, …
[PDF][PDF] Telemedicine supported strengthening of primary care in WHO South East Asia region: lessons from the COVID-19 pandemic experiences
N Gudi, R Konapur, O John, S Sarbadhikari, M Landry - BMJ Innov, 2021 - academia.edu
The COVID-19 pandemic has exposed the fragmentation of the healthcare delivery systems
and highlighted the role of resilient primary healthcare systems for a robust public health …
and highlighted the role of resilient primary healthcare systems for a robust public health …
[HTML][HTML] Regulatory frameworks for clinical trial data sharing: scoping review
…, SS Parsekar, SN Sarbadhikari, O John - Journal of medical …, 2022 - jmir.org
Background Although well recognized for its scientific value, data sharing from clinical trials
remains limited. Steps toward harmonization and standardization are increasing in various …
remains limited. Steps toward harmonization and standardization are increasing in various …
[HTML][HTML] A randomized, controlled trial of an aerosolized vaccine against measles
…, KE Brown, D Brown, JB Fink, O John… - … England Journal of …, 2015 - Mass Medical Soc
Background Aerosolized vaccine can be used as a needle-free method of immunization
against measles, a disease that remains a major cause of illness and death. Data on the …
against measles, a disease that remains a major cause of illness and death. Data on the …
A randomized trial of nafamostat for Covid-19
…, BJ Hudson, V Jha, PR Jevaji, O John… - NEJM …, 2023 - evidence.nejm.org
Background Nafamostat mesylate is a potent in vitro antiviral agent that inhibits the host
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …